Steffen Walter - Immatics Chief Officer
| IMTX Stock | USD 7.59 0.01 0.13% |
Insider
Steffen Walter is Chief Officer of Immatics NV
| Age | 47 |
| Address | Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076 |
| Phone | 49 7071 5397 0 |
| Web | https://www.immatics.com |
Immatics Management Efficiency
The company has return on total asset (ROA) of (0.1217) % which means that it has lost $0.1217 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2432) %, meaning that it created substantial loss on money invested by shareholders. Immatics' management efficiency ratios could be used to measure how well Immatics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. At this time, Immatics' Net Tangible Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 3.1 M in 2024, whereas Total Assets are likely to drop slightly above 298.3 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sushil Patel | Replimune Group | 53 | |
| Simon MBBS | Keros Therapeutics | 54 | |
| Prof MD | Lyell Immunopharma | N/A | |
| Richard Heyman | Syndax Pharmaceuticals | 67 | |
| Christopher MSc | Keros Therapeutics | 50 | |
| Cornelis Kruif | Merus BV | 59 | |
| Mark Lappe | Inhibrx | 57 | |
| Crystal MD | Lyell Immunopharma | 63 | |
| Timothy Pigot | Aerovate Therapeutics | 53 | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| Gary Lee | Lyell Immunopharma | 47 | |
| Jean Franchi | Replimune Group | 58 | |
| Jeff Knight | Crinetics Pharmaceuticals | 53 | |
| Sharon Goldbach | Harmony Biosciences Holdings | N/A | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| Anne McKay | Fennec Pharmaceuticals | 70 | |
| CFA CPA | Janux Therapeutics | 45 | |
| George Eldridge | Aerovate Therapeutics | 61 | |
| Anjali Ganguli | Syndax Pharmaceuticals | 47 | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| Hunter MD | Aerovate Therapeutics | 58 | |
Management Performance
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.12 |
Immatics NV Leadership Team
Elected by the shareholders, the Immatics' board of directors comprises two types of representatives: Immatics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immatics. The board's role is to monitor Immatics' management team and ensure that shareholders' interests are well served. Immatics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immatics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| PHR MBA, Director HR | ||
| Andrea Mokler, VP Sciences | ||
| Edward Sturchio, General Secretary | ||
| Arnd MBA, Chief Officer | ||
| Kristijan Lasic, Director Accounting | ||
| Miriam Meyer, VP Affairs | ||
| Toni Weinschenk, CoFounder Officer | ||
| Evelyn RothGeissler, VP Operations | ||
| Anja BSc, Director Communications | ||
| Carsten MD, Chief Officer | ||
| HansGeorg Rammensee, CoFounder Board | ||
| Steffen Walter, Chief Officer | ||
| Cedrik MD, Chief Officer | ||
| Dominik Maurer, Senior Unit | ||
| Edward JD, General Secretary | ||
| Harpreet Singh, MD, CEO | ||
| Ali Mohamed, Senior CMC | ||
| Emmanuelle MBA, VP Head | ||
| Ephraim MSc, Vice Accounting | ||
| Rainer Kramer, Chief Munich | ||
| Jordan Silverstein, Head Strategy |
Immatics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immatics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.42) % | ||||
| Current Valuation | 425.85 M | ||||
| Shares Outstanding | 121.55 M | ||||
| Shares Owned By Insiders | 22.16 % | ||||
| Shares Owned By Institutions | 68.72 % | ||||
| Number Of Shares Shorted | 6.69 M | ||||
| Price To Earning | 44.61 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immatics Stock Analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.